Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new Oxford Sparks animation with Hazel Hall-Roberts (Alzheimer’s Research UK Oxford Drug Discovery Institute) explores how researchers at the University of Oxford are working to discover new treatments for Alzheimer's.

Your beautiful, complex brain is a network of microscopic cells that connect together to form your thoughts and personality, and control your body. The network is fragile and requires constant upkeep, like a garden. The brain has its own gardeners, specialised cells called microglia.

In this new animation, Oxford Sparks look at how researchers at the University of Oxford are developing drug treatments for Alzheimer’s disease, by harnessing the power of the brain’s microglia. Watch the animation below. 

 

Oxford Sparks is an online platform that highlights the scientific research carried out at the University through exciting videos, animations and podcasts aimed at a public audience. Scientists from the Division have worked with Oxford Sparks to produce a variety of digital content that explains their innovative research to a wider audience, including a large number of exciting animations and this new podcast series. 

Find out more

Similar stories

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

Parental mental health worsens under new national COVID-19 restrictions

Coronavirus COVID-19 General Research

Parental stress, depression and anxiety have again increased since new national restrictions have been introduced, according to the latest report from the Oxford University-led COVID-19 Supporting Parents, Adolescents, and Children in Epidemics (Co-SPACE) study, based on data from over 6000 UK parents.

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

Awards and Appointments General Innovation

A new state of the art institute for antimicrobial research is to open at Oxford University thanks to a £100 million donation from Ineos.